|
2026 Journal Article “It Will Only Work If Everyone is on Board”: A Needs and Context Assessment to Inform Exercise Oncology Implementation Within a Public Healthcare OrganisationWhite, Georgia L., Kennedy, Mary A., Chan, Bryan A., Wright, Hattie and Rose, Grace L. (2026). “It Will Only Work If Everyone is on Board”: A Needs and Context Assessment to Inform Exercise Oncology Implementation Within a Public Healthcare Organisation. Asia-Pacific Journal of Clinical Oncology ajco.70158. doi: 10.1111/ajco.70158 |
|
2026 Journal Article SKYSCRAPER-05: A Phase 2 Study of Perioperative Tiragolumab Plus Atezolizumab, With or Without Platinum-Based Chemotherapy, in Patients With Previously Untreated, Locally Advanced, Resectable, Stage II‒IIIB Non-Small Cell Lung CancerShu, Catherine A., Kim, Anthony W., Hong, Min Hee, Martinez Marti, Alex, Früh, Martin, Ferris, Andrea, Pass, Harvey, Chan, Bryan A., Waqar, Saiama N., Bernaards, Coen A., Patil, Namrata S., Hsu, Jessie J., Parsons, Cristal, Troutman, Sarah, Matheny, Christina, Li, Pao-Chen, Gitlitz, Barbara and Felip, Enriqueta (2026). SKYSCRAPER-05: A Phase 2 Study of Perioperative Tiragolumab Plus Atezolizumab, With or Without Platinum-Based Chemotherapy, in Patients With Previously Untreated, Locally Advanced, Resectable, Stage II‒IIIB Non-Small Cell Lung Cancer. JTO Clinical and Research Reports 101047, 101047. doi: 10.1016/j.jtocrr.2026.101047 |
|
2026 Journal Article Treatment‐related adverse events and health‐related quality of life associated with immune checkpoint inhibitor treatment for mucosal head and neck squamous cell carcinoma: a scoping reviewO'Donnell, N. D., Ward, E. C., Wishart, L. R., Perera, R., Barrett, C., Edmiston, K. A., Mitchell, E., Pigott, A., Pitt, R., Russell, K., Chan, B. A. and Ladwa, R. (2026). Treatment‐related adverse events and health‐related quality of life associated with immune checkpoint inhibitor treatment for mucosal head and neck squamous cell carcinoma: a scoping review. Head and Neck hed.70306. doi: 10.1002/hed.70306 |
|
2026 Conference Publication First-line (1L) olomorasib + pembrolizumab in patients with KRAS G12C–mutant advanced NSCLC, and PD-L1 expression 0-49%, from the dose optimization cohorts of LOXO-RAS-20001 and SUNRAY-01Chan, Bryan Anthony, Peters, Solange, Leon, Luis, Yamada, Tadaaki, Makani, Neeharika Srivastava, Huang, Wen-Tsung, Spyratos, Dionisios, Roubec, Jaromir, Reinmuth, Niels, Sacher, Adrian G., Spira, Alexander I., Singhal, Nimit, Takeuchi, Shinji, Murciano-Goroff, Yonina R., Zhou, Yanhong, Fink, Aaron Alan, Merced, Alyson, Willard, Melinda D., Visseren Grul, Carla M. and Johnson, Melissa Lynne (2026). First-line (1L) olomorasib + pembrolizumab in patients with KRAS G12C–mutant advanced NSCLC, and PD-L1 expression 0-49%, from the dose optimization cohorts of LOXO-RAS-20001 and SUNRAY-01. 2026 ASCO Annual Meeting, Chicago, IL United States, 29 May-2 June 2026. Alexandria, VA United States: American Society of Clinical Oncology. doi: 10.1200/jco.2026.44.16_suppl.8628 |
|
2026 Journal Article Phase II trial of first-line durvalumab and chemotherapy in patients with extra-pulmonary small cell carcinomaKok, Peey-Sei, Chan, Bryan, Aberoumoud, Mason, Zhang, Alison, O’Byrne, Ken, Thavaneswaran, Subotheni, Lin, Frank, Kansara, Maya, Corpuz, Theresa, Wheeler, Patrick, Simes, Robert John, Thomas, David and Lee, Chee Khoon (2026). Phase II trial of first-line durvalumab and chemotherapy in patients with extra-pulmonary small cell carcinoma. JTO Clinical and Research Reports, 7 (7) 101014, 101014-7. doi: 10.1016/j.jtocrr.2026.101014 |
|
2026 Journal Article 440TiP A phase II/III trial of a PD-1/VEGF bispecific antibody (PF-08634404) in combination with chemotherapy in first-line for extensive-stage small cell lung cancer (Symbiotic-Lung-04)Cappuzzo, F., Schaefer, E., Yamanaka, Y., Chan, B.A., Nagrial, A.M., Wu, Y-L., Planchard, D., Gröpper, S., Simoes Da Rocha, P.F., Novello, S., Park, J., Huang, M. and Dowlati, A. (2026). 440TiP A phase II/III trial of a PD-1/VEGF bispecific antibody (PF-08634404) in combination with chemotherapy in first-line for extensive-stage small cell lung cancer (Symbiotic-Lung-04). ESMO Open, 11 106754, 106754. doi: 10.1016/j.esmoop.2026.106754 |
|
2026 Journal Article Kirsten rat sarcoma viral oncogene homolog (KRAS) mutation testing trends, prevalence, and outcomes in metastatic, non-squamous non-small cell lung cancer (non-SQ NSCLC) patients in Queensland, Australia from 2014–2023Niranjan, Navin, Guan, Tracey, Niranjan, Nitin, Taherian Fard, Atefeh, Youlden, Danny R., Mason, Robert, Chan, Bryan A. and Sanmugarajah, Jasotha (2026). Kirsten rat sarcoma viral oncogene homolog (KRAS) mutation testing trends, prevalence, and outcomes in metastatic, non-squamous non-small cell lung cancer (non-SQ NSCLC) patients in Queensland, Australia from 2014–2023. Thoracic Cancer, 17 (7) e70274. doi: 10.1111/1759-7714.70274 |
|
2026 Journal Article Management of bone health in cancer survivorship: a systematic review of clinical guidelinesLi, Victor Ki Chung, Cosgrove, Stirling, Collins, Katelyn, Baden, Paul, Blennerhassett, Richard, Chan, Bryan A., Chan, Li-Heng, Day, Daphne, Goodwin, Belinda, Kwok, Alastair, Packham, Debbie, Kyaw, Kaung Tha, Todaro, Christopher, Webber, Kate, Williams, Janne, Zengin, Ayse and Grech, Lisa (2026). Management of bone health in cancer survivorship: a systematic review of clinical guidelines. Osteoporosis International. doi: 10.1007/s00198-026-07924-8 |
|
2026 Conference Publication Olomorasib+Pembrolizumab in KRAS G12C-Mutant NSCLC: Results from LOXO-RAS-20001 and SUNRAY-01Johnson, M L, Mateos, L L, Yamada, T, Makani, N, Chan, B, Huang, W-T, Spyratos, D, Roubec, J, Reinmuth, N, Sacher, A, Spira, A, Singhal, N, Takeuchi, S, Murciano-Goroff, Y, Zhou, Y, Fink, A, Fasnacht, N, Willard, M, Visseren-Grul, C, Peters, S and Wesseler, C (2026). Olomorasib+Pembrolizumab in KRAS G12C-Mutant NSCLC: Results from LOXO-RAS-20001 and SUNRAY-01. STUTTGART: Georg Thieme Verlag KG. doi: 10.1055/s-0046-1816480 |
|
2026 Journal Article Facilitators to the implementation of exercise into cancer care: a systematic reviewWhite, Georgia L., Kennedy, Mary A., Cunningham, Brent J., Dunn, Riley, Martin, Jason, Walker, Meegan, Wallington-Gates, Craig T., Wright, Hattie, Chan, Bryan and Rose, Grace L. (2026). Facilitators to the implementation of exercise into cancer care: a systematic review. Journal of Cancer Survivorship. doi: 10.1007/s11764-025-01948-5 |
|
2026 Journal Article Evolving patterns of care, outcomes and ongoing challenges for early‐stage non‐small cell lung cancer in the immunotherapy era: a Queensland population‐based studyChan, Bryan A., Youlden, Danny R., Pattison, Andrew, Guan, Tracey, Cossio, Danica and Sanmugarajah, Jasotha (2026). Evolving patterns of care, outcomes and ongoing challenges for early‐stage non‐small cell lung cancer in the immunotherapy era: a Queensland population‐based study. Thoracic Cancer, 17 (2) e70185, 1-12. doi: 10.1111/1759-7714.70185 |
|
2025 Conference Publication Phase II trial of first-line durvalumab and chemotherapy in patients with extra-pulmonary small cell carcinomaKok, P. S., Chan, B., Zhang, A., O'byrne, K., Aberoumoud, M., Thavaneswaran, S., Lin, F. P., Kansara, M., Corpuz, T., Wheeler, P., Simes, J., Thomas, D. M. and Lee, C. K. (2025). Phase II trial of first-line durvalumab and chemotherapy in patients with extra-pulmonary small cell carcinoma. AMSTERDAM: ELSEVIER. doi: 10.1016/j.annonc.2025.10.1018 |
|
2025 Journal Article Setting the benchmark: patterns of care and outcomes for early-stage non-small cell lung cancer in Queensland, Australia, 2011-2017Chan, Bryan A., Youlden, Danny R., Guan, Tracey, Lehman, Margot, Windsor, Morgan, Bolton, Alison, Dunn, Nathan, Cossio, Danica, Philpot, Shoni and Sanmugarajah, Jasotha (2025). Setting the benchmark: patterns of care and outcomes for early-stage non-small cell lung cancer in Queensland, Australia, 2011-2017. Asia-Pacific Journal of Clinical Oncology, 21 (6), 597-606. doi: 10.1111/ajco.14177 |
|
2025 Conference Publication Efficacy and Safety of 1L Olomorasib Plus Pembrolizumab in KRAS G12C-Mutant NSCLC: Results From LOXO-RAS-20001 and SUNRAY-01Johnson, M. L., Mateos, L. L., Yamada, T., Makani, N., Chan, B., Huang, W. T., Spyratos, D., Roubec, J., Reinmuth, N., Sacher, A., Spira, A. I., Singhal, N., Takeuchi, S., Murciano-Goroff, Y. R., Zhou, Y., Fink, A. A., Merced, A., Willard, M. D., Visseren-Grul, C. and Peters, S. (2025). Efficacy and Safety of 1L Olomorasib Plus Pembrolizumab in KRAS G12C-Mutant NSCLC: Results From LOXO-RAS-20001 and SUNRAY-01. NEW YORK: ELSEVIER SCIENCE INC. |
|
2025 Conference Publication Primary Endpoint Results from SHERLOCK: a Phase 2 trial of Sotorasib, Bevacizumab and Chemotherapy in Advanced<i> KRAS</i> G12C NSCLCLee, C. K., Zhou, D. d. -x., Brown, C. S. B., Bray, V., Ding, P., Itchins, M., Hughes, B. G. M., Houghton, B., Chan, B., Black, A., Solomon, B. J., Roberts-Thomson, R., Mersiades, A. J., Parakh, S., Bain, N., Yip, S., Barton, K., Cummins, M. M., Wall, M., Goodwin, A., Stockler, M., Pavlakis, N., John, T. and Arulananda, S. (2025). Primary Endpoint Results from SHERLOCK: a Phase 2 trial of Sotorasib, Bevacizumab and Chemotherapy in Advanced KRAS G12C NSCLC. NEW YORK: ELSEVIER SCIENCE INC. |
|
2025 Journal Article Treatment and survival for unresectable pancreatic adenocarcinoma in Queensland, Australia, 2018–2022Youlden, Danny R., Chan, Bryan A., Clark, Jon, Donoghue, Victoria K. and Allen, Michael J. (2025). Treatment and survival for unresectable pancreatic adenocarcinoma in Queensland, Australia, 2018–2022. Cancer Medicine, 14 (17) e71226, 1-10. doi: 10.1002/cam4.71226 |
|
2025 Journal Article Triage tools to inform the prioritisation of physical health services following a diagnosis of cancer: a scoping reviewWhite, Georgia L., Capozzi, Lauren C., Linton, Corey, Wright, Adrian, Jones, Tamara, Wright, Hattie H., Bolam, Kate A., Johnston, Elizabeth A., Clifford, Briana K., Bean, Keegan, Brown, Stephanie, Kolesaric, Sarah, Kennedy, Mary A., Chan, Bryan A. and Rose, Grace L. (2025). Triage tools to inform the prioritisation of physical health services following a diagnosis of cancer: a scoping review. Supportive Care in Cancer, 33 (9) 760, 1-13. doi: 10.1007/s00520-025-09816-9 |
|
2025 Journal Article Quality indicators for non‐small cell lung cancer in Queensland, Australia, 2012–2021Youlden, Danny R., Guan, Tracey, Chan, Bryan A., Sanmugarajah, Jasotha, Lehman, Margot, Windsor, Morgan, Bolton, Alison, Nath, Artika, Dunn, Nathan and Cossio, Danica (2025). Quality indicators for non‐small cell lung cancer in Queensland, Australia, 2012–2021. Thoracic Cancer, 16 (5) e70034, e70034. doi: 10.1111/1759-7714.70034 |
|
2024 Journal Article Real‐world outcomes for patients with pleural mesothelioma: a multisite retrospective cohort studyChow, Kar Ven Cavan, Turner, Cassie, Hughes, Brett, Lwin, Zarnie and Chan, Bryan (2024). Real‐world outcomes for patients with pleural mesothelioma: a multisite retrospective cohort study. Asia-Pacific Journal of Clinical Oncology, 20 (6), 723-730. doi: 10.1111/ajco.14098 |
|
2024 Conference Publication Reducing preventable emergency visits: results from the Oncology Nurse Practitioner-led Rapid Access Clinic (RACE) service at a tertiary regional cancer centreMazza, Cassandra, O'Neill, Martina, Ringshaw, Kacy, Collins, Kelly, O'Riley, Lily, Danielsen-Jensen, Madeline, Bradford, Natalie, Gavin, Nicole, Brunelli, Vanessa N. and Chan, Bryan A. (2024). Reducing preventable emergency visits: results from the Oncology Nurse Practitioner-led Rapid Access Clinic (RACE) service at a tertiary regional cancer centre. COSA's 51st Annual Scientific Meeting, Gold Coast, QLD, Australia, 13-15 November 2024. Chichester, West Sussex, United Kingdom: Wiley-Blackwell Publishing. doi: 10.1111/ajco.14116 |
